Sierra Leone
Tuberculosis profile
| High HIV burden |
Population  2012 6 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 8.5 (3.2–16) 143 (53–275)
Mortality (HIV+TB only) 2 (1.6–2.2) 33 (27–38)
Prevalence  (includes HIV+TB) 78 (37–130) 1 304 (626–2 222)
Incidence  (includes HIV+TB) 40 (32–49) 674 (540–821)
Incidence (HIV+TB only) 3.9 (3.2–4.8) 66 (53–81)
Case detection, all forms (%) 32 (27–40)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 8 031 (63) Relapse 232 (45)
Smear-negative 2 610 (20) Treatment after failure 94 (18)
Smear-unknown / not done 1 631 (13) Treatment after default 186 (36)
Extrapulmonary 570 (4) Other    
Other          
Total new 12 842   Total retreatment 512  
           
Other (history unknown)          
Total new and relapse 13 074   Total cases notified 13 354  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 1.6 1.4 1.3
Age < 15 150 1 445 215
Laboratories 2012
Smear (per 100 000 population) 2.7
Culture (per 5 million population) 0
Drug susceptibility testing (per 5 million population) 0
Is second-line drug susceptibility testing available? No
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 88   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 85  
Retreatment 70  
TB/HIV 2012 Number (%)
TB patients with known HIV status 11 655 (87)
HIV-positive TB patients 1 343 (12)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 344 (26)
HIV-positive TB patients on antiretroviral therapy (ART) 931 (69)
HIV-positive people screened for TB 8 934  
HIV-positive people provided with IPT 1 062  
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 0.85 (0.02–4.7) 23 (5–54)
MDR-TB cases among notified pulmonary
TB cases
100 (3–570) 120 (26–280)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB      
Laboratory-confirmed MDR-TB cases      
Patients started on MDR-TB treatment      
Financing TB control 2013
National TB programme budget (US$ millions) <1
% Funded domestically 9%
% Funded internationally 264%
% Unfunded <1%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-24 Data: www.who.int/tb/data